Skip to content
    VEEV
    Earnings call· Jan 2025(Q4 FY25)

    VEEVA SYSTEMS INC VEEV

    Mar 5, 2025 Source

    Executive summary

    Veeva Systems Q4 FY25 — Strong Finish to the Year with Strategic Wins and Innovation

    Veeva Systems concluded FY25 with robust Q4 results, surpassing guidance across key financial metrics, driven by strong execution and product innovation. The company secured a significant 'all-in' clinical platform deal with a top 20 pharma, highlighting a trend towards integrated solutions. While preparing for future growth with a 2030 revenue target of $6 billion and new market expansions, Veeva navigates a slight deceleration in subscription growth for FY26, largely due to prior-year outperformance and FX headwinds, maintaining focus on product excellence and customer-friendly transitions for Vault CRM.

    Highlights

    5

    • Total revenue in Q4 FY25 reached $721 million, exceeding guidance.

    • Non-GAAP operating income for Q4 FY25 was $308 million, contributing to a full-year non-GAAP operating income of $1.15 billion.

    • Secured an 'all-in' clinical platform deal with a top 20 pharma customer, demonstrating strategic vendor consolidation.

    • Added 20 new Vault CRM clients in Q4 FY25, primarily small to mid-sized companies selecting their first CRM system.

    • Achieved 17 out of top 20 pharma using CTMS and 9 out of top 20 pharma committing to Veeva EDC.

    Concerns

    2

    • Subscription growth is projected to decelerate from 20% in FY25 to 13% in FY26 (implied in guide), primarily due to a tough compare for Crossix and normalization post-T4C.

    • Anticipates a 1% revenue growth headwind from foreign exchange in FY26.

    Guidance & targets

    5
    CategoryTargetConfidence
    Total Revenue
    $6 billion
    high materiality
    High
    Vault CRM Top 20 Customer Decisions
    Vast majority of decisions
    high materiality
    High
    Non-GAAP Operating Margin
    above 42%
    medium materiality
    High
    Subscription Revenue Growth (ex-FX)
    about 14%
    high materiality
    High
    FX Revenue Headwind
    1%
    medium materiality
    High

    Operational metrics

    9
    Non-GAAP Operating Income
    $308 million
    Q4 FY25

    Reported for the quarter.

    Non-GAAP Operating Income
    $1.15 billion
    FY25

    Reported for the full fiscal year.

    Subscription Revenue Growth
    20%vs. 13% implied FY26 guide
    FY25

    Analyst stated 20% growth last year in fiscal '25, compared to 13% implied in FY26 guide. Normalized for T4C impact, FY25 subscription growth was 15%.

    Collections Impact
    $50 million
    Prior Year

    One-time impact of collections pushing from the prior year, making for a harder year-over-year compare for cash flow.

    Services Team Utilization
    120%
    Boom times

    Veeva's services team flexes utilization, running hot at 120% during boom times, demonstrating ability to meet demand.

    Top 20 Pharma using CTMS
    17
    Q4 FY25

    Number of top 20 pharma customers standardizing on Veeva's CTMS.

    Top 20 Pharma using EDC
    9
    Q4 FY25

    Number of top 20 pharma customers committed to Veeva EDC, with steady advancement.

    Vault CRM New Customers
    20
    Q4 FY25

    New Vault CRM clients, mostly small and mid-sized companies in the U.S. market, selecting their first CRM system.

    Veeva Pulse First Deal Value
    7-figure
    Q4 FY25

    First deal signed for the new Veeva Pulse product, with a top 20 pharma in the U.S.

    Industry KPIs

    4
    MetricValueDetails
    Adjusted EBITDA$308 millionUSD
    Healthcare client count20customers
    Revenue adjusted EBITDA guidanceabove 42%%
    Subscription recurring revenue growth14%%

    Product announcements

    5
    ProductTypeDetails
    Veeva Pulselaunch
    Direct Data APIupdate
    CRM Voice Controlroadmap
    CRM botroadmap
    MLR bot (Medical Legal Regulatory Review bot)roadmap

    Deals & partnerships

    1
    Top 20 Pharma CustomerAll-in clinical platform dealLarge dealApproximately 5 years

    Customer committed to Veeva's full clinical platform, driven by desire for speed and efficiency in decision-making and aligning clinical teams. This is one of Veeva's longer ramps.

    Risks & headwinds

    2
    Potential impact of changes to indirect research funding (e.g., NIH)Early, ongoing

    Not quantified, 'early to predict exactly what the impact may or may not be'.

    Mitigation: Life sciences industry is generally resilient and adaptable; Veeva's revenue is predictable with annual subscriptions, projects typically come back if delayed.

    Potential disruption from tariffs and supply chain changesEarly, in flux

    Not quantified

    Mitigation: If disruption occurs, it would delay contracts but not lose opportunity; no sign of impact yet.

    What to watch in Q1 FY26

    5

    Vault CRM Top 20 Customer Decisions

    2025
    CurrentDiscussions ongoing with all top 20
    TargetMore announcements in 2025

    Why it matters

    Indicates progress on a key strategic initiative and future revenue growth for Vault CRM.

    But we want it to happen on the customer's time frame. And having said that, we expect more announcements in 2025. And I expect the vast majority of decisions, particularly in top 20, will happen by the end of 2026.

    Q&A highlights

    7

    Is the 'all-in' deal driven by risk reduction/consolidation, and what does it mean for future strategic transactions?

    Peter explained the 'all-in' deal was primarily about speed and efficiency for the customer, enabling a combined decision for the full clinical platform and better alignment of clinical teams. He noted that top 20 pharma focus on competitive advantage and standardization, not risk avoidance. While Veeva is becoming more strategic with customers, each top 20 will follow a different path.

    “I think this is really about -- for this particular customer, this is really about speed, just more efficient to make a combined decision for the full clinical platform and a better way to align their different clinical teams onto a shared goal and shared technology.”

    asked by Joseph Vruwink · answered by Peter Gassner

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Clinical Platform Wins

    Veeva secured a significant 'all-in' clinical platform deal with a top 20 pharma customer, driven by the customer's desire for speed and efficiency in decision-making and aligning clinical teams. This deal, expected to ramp over approximately five years, highlights a trend towards integrated solutions. The company has seen 17 of the top 20 pharma using CTMS and 9 of the top 20 committing to Veeva EDC, demonstrating increasing standardization on Veeva's integrated clinical operations and data management systems.

    02

    AI Strategy and Product Development

    Peter Gassner noted that the AI technology landscape is stabilizing, allowing Veeva to focus on specific, workflow-integrated AI solutions. Upcoming products include CRM voice control, CRM bot, and the MLR bot (medical legal regulatory review bot), all planned for release this year. Veeva has centralized its AI development group to build core competency, believing its timing is optimal now that the foundational technology is more stable.

    03

    Data Cloud Momentum and New Products

    There is growing interest in Veeva's Data Cloud offerings, encompassing Compass, OpenData, Link, and the newly announced Pulse. Progress in Compass is primarily with Patient data, though enterprise license agreements (ELAs) are anticipated within the next year or so. The new Veeva Pulse product, which generates privacy-safe data from CRM activity for segmentation and targeting, has already secured its first 7-figure deal with a top 20 pharma in the U.S. International expansion for Pulse into Southeast Asia, Japan, and potentially more European countries is planned by 2026.

    04

    Vault CRM Transition and Customer Adoption

    Veeva added 20 new Vault CRM clients in Q4 FY25, predominantly small to mid-sized companies adopting their first CRM system. Discussions with top 20 pharma customers for Vault CRM migration are progressing, with the vast majority of decisions expected by the end of 2026. Management emphasized that customers are increasingly aware of a 'red zone' for migration decisions, indicating a limited timeframe for transitioning from legacy systems.

    05

    Operational Efficiency and Investment

    Veeva's strong non-GAAP operating margin guidance for FY26 (above 42%) is attributed to broad-based efficiency gains across sales, marketing, and product teams. The company prioritizes investing in R&D (spending twice as much as on sales and marketing) to drive product excellence and innovation. Mechanical efficiencies are also gained as more products are developed on the Veeva Vault platform, leading to economies of scale and improved platform capabilities.

    06

    New Market Expansion (Horizontal Apps)

    Peter Gassner discussed Veeva's long-term plan to expand into new markets with horizontal applications. He believes there is an opportunity for 'version 2' application tech platforms, contrasting them with current 'version 1' cloud SaaS applications. The focus is on platform innovation, designed with future AI integration and user interface changes in mind, to leverage core learnings and create compounding effects, though no specific application areas have been announced yet.

    AI-generated summary of the company’s earnings call. Not investment advice.